REVIEW PAPER
Variety of allergic symptoms in the therapy of selected respiratory and autoimmune diseases
1
Student Scientific Group of Internal Medicine and Allergology, Faculty of Medicine, Medical University, Wrocław, Poland
2
Department of Internal Medicine, Pneumology and Allergology, Faculty of Medicine, Medical University, Wrocław, Poland
Corresponding author
Patrycja Kozubek
Student Scientific Group of Internal Medicine and Allergology, Faculty of Medicine, Medical University, 50–368 Wrocław, Poland
Student Scientific Group of Internal Medicine and Allergology, Faculty of Medicine, Medical University, 50–368 Wrocław, Poland
Med Srod. 2024;27(3):131-136
KEYWORDS
diabetes mellituscystic fibrosisanaphylaxisdrug hypersensitivityinflammatory bowel diseasesallergic reactions
TOPICS
ABSTRACT
Introduction and objective:
Drug hypersensitivity reactions are common in the therapy of various diseases. The Gell and Coombs classification divides immunologic drug hypersensitivity reactions into four major pathophysiologic categories based on immunologic mechanism (I, II, III, IV). The reactions may occur during the treatment of cystic fibrosis and autoimmune diseases, such as diabetes and inflammatory bowel diseases. Allergy symptoms can vary from mild, local reactions to severe anaphylaxis requiring hospitalization. The aim of this review is to systematize the latest knowledge on the diversity of allergic reactions to various types of treatment of common autoimmune and respiratory diseases and show the need for future research in this field.
Brief description of the state of knowledge:
Allergic reactions may include fever, nausea, vomiting, hypotension, haemolytic anaemia, joint swelling, itching, rash with eosinophilia, urticaria and many more. To confirm hypersensitivity, it is important to conduct an extensive interview, confirm the proper use of the preparation, and conduct allergy tests. The study presents allergic reactions in the treatment of the following diseases: cystic fibrosis, inflammatory bowel diseases and diabetes mellitus.
Summary:
Allergic reactions may vary depending on the type of treatment and patient›s predispositions. Undeniably, the occurrence of side-effects in the form of allergic reactions negatively affects the results of therapy and the patient›s quality of life. Further research is needed on how to avoid allergic side-effects and treatment options for those already developed without the need to prematurely terminate therapy.
Drug hypersensitivity reactions are common in the therapy of various diseases. The Gell and Coombs classification divides immunologic drug hypersensitivity reactions into four major pathophysiologic categories based on immunologic mechanism (I, II, III, IV). The reactions may occur during the treatment of cystic fibrosis and autoimmune diseases, such as diabetes and inflammatory bowel diseases. Allergy symptoms can vary from mild, local reactions to severe anaphylaxis requiring hospitalization. The aim of this review is to systematize the latest knowledge on the diversity of allergic reactions to various types of treatment of common autoimmune and respiratory diseases and show the need for future research in this field.
Brief description of the state of knowledge:
Allergic reactions may include fever, nausea, vomiting, hypotension, haemolytic anaemia, joint swelling, itching, rash with eosinophilia, urticaria and many more. To confirm hypersensitivity, it is important to conduct an extensive interview, confirm the proper use of the preparation, and conduct allergy tests. The study presents allergic reactions in the treatment of the following diseases: cystic fibrosis, inflammatory bowel diseases and diabetes mellitus.
Summary:
Allergic reactions may vary depending on the type of treatment and patient›s predispositions. Undeniably, the occurrence of side-effects in the form of allergic reactions negatively affects the results of therapy and the patient›s quality of life. Further research is needed on how to avoid allergic side-effects and treatment options for those already developed without the need to prematurely terminate therapy.
REFERENCES (50)
1.
Dragostin I, Dragostin OM, Lisă EL, et al. Drugs frequently involved in inducing hypersensitivity reactions. Drug Chem Toxicol. 2022;45(2):617–624, https://doi.org/10.1080/014805....
2.
Kramer EL, Hudock KM, Davidson CR, et al. CFTR Dysfunction in Smooth Muscle Drives TGFβ Dependent Airway Hyperreactivity. Respir Res. 2023;24. https://doi.org/10.1186/S12931....
3.
López-Valdez JA, Aguilar-Alonso LA, Gándara-Quezada V, et al. Cystic Fibrosis: Current Concepts. Bol Med Hosp Infant Mex. 2021;78:584–596. https://doi.org/10.24875/BMHIM....
4.
Rafeeq MM, Murad HAS. Cystic Fibrosis: Current Therapeutic Targets and Future Approaches. J Transl Med. 2017;15. https://doi.org/10.1186/S12967....
5.
Braun C, Reix P, Durieu I, et al. The Diagnosis of Hypersensitivity to Antibiotics Is Rarely Confirmed by Allergy Work-up in Cystic Fibrosis Patients. Pediatr Allergy Immunol. 2020;31:396–404. https://doi.org/10.1111/PAI.13....
6.
Kowalik A, de Monestrol I, Sorjonen K, et al. Antibiotic Hypersensitivity in Cystic Fibrosis – Low Frequency of Anaphylaxis over 16 000 Courses. Br J Clin Pharmacol. 2022;88:4845–4853. https://doi.org/10.1111/BCP.15....
7.
Van Der Meer R, Touw DJ, Heijerman HGM. Prevention of Drug-Related Complications in Cystic Fibrosis. Curr Opin Pulm Med. 2019;25: 666–673. https://doi.org/10.1097/MCP.00....
8.
Wright MFA, Bush A, Carr SB. Hypersensitivity Reactions to Intravenous Antibiotics in Cystic Fibrosis. Paediatr Respir Rev. 2018;27:9–12. https://doi.org/10.1016/J.PRRV....
9.
Abuzgaia AM, Elzagallaai AA, Mullowney T, et al. Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk. Mol Diagn Ther. 2023;27:395–403. https://doi.org/10.1007/S40291....
10.
Abushahin A, Toma H, Hamad SG, et al. Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome in a Child with Cystic Fibrosis. Case Reports Immunol. 2023;2023. https://doi.org/10.1155/2023/1....
11.
Gohy S, Froidure A, Lebecque P. DRESS Syndrome in a Patient with Cystic Fibrosis: A Case Report. Pediatr Pulmonol. 2017;52:E18–E21. https://doi.org/10.1002/PPUL.2....
12.
Kohn V, Carrizo D, Arato G, et al. DRESS Syndrome in a Patient with Cystic Fibrosis: A Pediatric Case Report Arch Argent Pediatr. 2021;119:E234–E238. https://doi.org/10.5546/AAP.20....
13.
Tugcu GD, Emiralioglu N, Yalcin E, et al. The Controversy of Drug Hypersensitivity in Patients with Cystic Fibrosis and Review of the Literature. Pediatr Allergy Immunol. 2022;33. https://doi.org/10.1111/PAI.13....
14.
Emeksiz ZŞ, Metbulut P, Akyan Soydaş ŞS, et al. Evaluation of Frequency and Characteristics of Drug Allergy in Pediatric Patients with Cystic Fibrosis. Pediatr Allergy Immunol Pulmonol. 2022;35:74–78. https://doi.org/10.1089/PED.20....
15.
Süleyman A, Tamay Z, Güler N. Antibiotic Allergy in Children with Cystic Fibrosis: A Retrospective Case-Control Study. Pediatr Pulmonol. 2022;57:2622–2628. https://doi.org/10.1002/PPUL.2....
16.
Muirhead C, Verzasconi D, Joshi S. At-Home Compounding Preparation of Slow Desensitization of Elexacaftor/Tezacaftor/Ivacaftor for Delayed Hypersensitivity Rash. Pediatr Pulmonol. 2022;57:1779–1781. https://doi.org/10.1002/PPUL.2....
17.
Roehmel JF, Ogese MO, Rohrbach A, et al. Drug Allergy to CFTR Modulator Therapy Associated with Lumacaftor-Specific CD4+ T Lymphocytes. J Allergy Clin Immunol. 2021;147:753–756. https://doi.org/10.1016/J.JACI....
18.
Lowry S, Mogayzel PJ, Oshima K, et al. Drug-Induced Liver Injury from Elexacaftor/Ivacaftor/Tezacaftor. J Cyst Fibros. 2022;21:e99–e101. https://doi.org/10.1016/J.JCF.....
19.
Tewkesbury D, Jones AM, Bright-Thomas R, et al. Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM. Drugs. 2023;83:1699–1707. https://doi.org/10.1007/S40265....
20.
Mederos-Luis E, González-Pérez R, Poza-Guedes P, et al. Toxic Epidermal Necrolysis Induced by Cystic Fibrosis Transmembrane Conductance Regulator Modulators. Contact Dermatitis. 2022;86:224–225. https://doi.org/10.1111/COD.14....
21.
Stallmach A, Atreya R, Grunert PC, et al. Treatment Strategies in Inflammatory Bowel Diseases. Dtsch Arztebl Int. 2023;120:768. https://doi.org/10.3238/ARZTEB....
22.
Sawata T, Bando M, Kogawara H, et al. Drug-Induced Hypersensitivity Syndrome Accompanied by Pulmonary Lesions Exhibiting Centrilobular Nodular Shadows. Internal Medicine. 2016;55:1159–1163. https://doi.org/10.2169/INTERN....
23.
Iida T, Hida T, Matsuura M, et al. Current Clinical Issue of Skin Lesions in Patients with Inflammatory Bowel Disease. Clin J Gastroenterol. 2019;12:501–510. https://doi.org/10.1007/S12328....
24.
Antonelli E, Bassotti G, Tramontana M, et al. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med. 2021;10:1–16. https://doi.org/10.3390/JCM100....
25.
Queiroz NSF, Regueiro M. Safety Considerations with Biologics and New Inflammatory Bowel Disease Therapies. Curr Opin Gastroenterol. 2020;36:257–264. https://doi.org/10.1097/MOG.00....
26.
Pauchard I, Nancey S, Hacard F, et al. Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases Who Experienced Acute Infusion Reactions. Digestive Diseases. 2018;36:417–426. https://doi.org/10.1159/000491....
27.
Nucera E, Andriollo G, Buonomo A, et al. Interesting Case of Infliximab IV Type Hypersensitivity. Inflamm Bowel Dis. 2019;25:e49–e51. https://doi.org/10.1093/IBD/IZ....
28.
Lee J, Lemons N, Lorenze A, et al. Management of Cutaneous Side Effects of Inflammatory Bowel Disease Therapy: A Dermatologic Viewpoint. J Gastroenterol Hepatol. 2021;36:3278–3285. https://doi.org/10.1111/JGH.15....
29.
Dias T, Santos A, Santos RM, et al. A. Case Report: Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis. BMJ Case Rep. 2019;12. https://doi.org/10.1136/BCR-20....
30.
Hirono H, Watanabe K, Hasegawa K, et al. A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions. Am J Case Rep. 2018;19:623. https://doi.org/10.12659/AJCR.....
31.
Matsumoto S, Mashima H. Mesalazine Allergy and an Attempt at Desensitization Therapy in Patients with Inflammatory Bowel Disease. Sci Rep 2020. 10;22176. https://doi.org/10.1038/S41598....
32.
Franco AI, Escobar L, García XA, et al. Mesalazine-Induced Eosinophilic Pneumonia in a Patient with Ulcerative Colitis Disease: A Case Report and Literature Review. Int J Colorectal Dis. 2016;31:927–929. https://doi.org/10.1007/S00384....
33.
Zgheib O, Trombert V, Jandus P, et al. Drug-Induced Hypersensitivity Syndrome with Lupus Manifestations Due to Mesalazine in a Patient with Ulcerative Colitis. BMJ Case Rep. 2022;15:248229. https://doi.org/10.1136/BCR-20....
34.
Loftus EV, Feaga BG, Panaccione R, et al. Long-term Safety of Vedolizumab for Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2020;52:1353. https://doi.org/10.1111/APT.16....
35.
Bailly E, Von Tokarski F, Beau-Salinas F, et al. Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report. American Journal of Kidney Diseases. 2018;71:142–145. https://doi.org/10.1053/j.ajkd....
36.
Xie Y, Li H, Zhou L, et al. A Case of Vedolizumab-Induced Acute Allergic Reaction in a Patient With Refractory Ulcerative Colitis. Inflamm Bowel Dis. 2022;28:e103–e103. https://doi.org/10.1093/IBD/IZ....
37.
Del Chierico F, Rapini N, Deodati A, et al. Pathophysiology of Type 1 Diabetes and Gut Microbiota Role. Int J Mol Sci. 2022;23. https://doi.org/10.3390/IJMS23....
38.
Aberumand B, Jeimy S. The Complexities of Insulin Allergy: A Case and Approach. Allergy Asthma Clin Immunol. 2021;17. https://doi.org/10.1186/S13223....
39.
Elfekih H, Hadjkacem F, Elleuch M, et al. Successful Treatment of Insulin Allergy with Desensitization Therapy: A Case Report and Literature Review. Iran J Allergy Asthma Immunol. 2019;18:572–583. https://doi.org/10.18502/IJAAI....
40.
Bavbek S, Lee MJ. Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies. Immunol Allergy Clin North Am. 2017;37:761–771, https://doi.org/10.1016/J.IAC.....
41.
Garg SK, Wernicke-Panten K, Wardecki M, et al. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020;22:85–95. https://doi.org/10.1089/DIA.20....
42.
Morton A, Laurie J. Allergic Reactions to Insulin Detemir in Women with Gestational Diabetes Mellitus. https://www.racgp.org.au/afp/2... Afp 2016.
43.
Yuan T, Zhao W, Wang L, et al. Continuous Subcutaneous Insulin Infusion as an Effective Method of Desensitization Therapy for Diabetic Patients with Insulin Allergy: A 4-Year Single-Center Experience. Clin Ther. 2016;38:2489–2494.e1. https://doi.org/10.1016/J.CLIN....
44.
Bzowyckyj AS, Stahnke AM. Hypersensitivity Reactions to Human Insulin Analogs in Insulin-Naïve Patients: A Systematic Review. Ther Adv Endocrinol Metab. 2018;9:53–65. https://doi.org/10.1177/204201....
45.
Alkhatib EH, Grundman JB, Adamusiak AM, et al. Case Report: Insulin Hypersensitivity in Youth with Type 1 Diabetes. Front Endocrinol. (Lausanne) 2023;14. https://doi.org/10.3389/FENDO.....
46.
Karimzadeh S, Lopes SA, Allali D, et al. JORNAYVAZ FR, Gariani K. [Insulin Allergy: How to Manage It?]. Rev Med Suisse. 2022;18:1100–1105. https://doi.org/10.53738/REVME....
47.
Alves da Silva C, Bregnhøj A, Mowitz M, et al. Contact Dermatitis in Children Caused by Diabetes Devices. Contact Dermatitis. 2022;87:406–413. https://doi.org/10.1111/COD.14....
48.
Cichoń M, Trzeciak M, Sokołowska-Wojdyło M, et al. Contact Dermatitis to Diabetes Medical Devices. Int J Mol Sci. 2023;24. https://doi.org/10.3390/IJMS24....
49.
Hartsough EM, Hylwa SA. Wearable Woes: Allergens in Diabetic Devices. Dermatitis. 2021;32:19–31, https://doi.org/10.1097/DER.00....
50.
Wen WL, Tsai KB, Lin YH, et al. Successful Management of Type IV Hypersensitivity Reactions to Human Insulin Analogue with Injecting Mixtures of Biphasic Insulin Aspart and Dexamethasone. J Formos Med Assoc. 2019;118:843–848. https://doi.org/10.1016/J.JFMA....
| eISSN: | 2084-6312 |
| ISSN: | 1505-7054 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
